Literature DB >> 32771640

Increased Complement Receptor-3 levels in monocytes and granulocytes distinguish COVID-19 patients with pneumonia from those with mild symptoms.

Rajeev Gupta1, Vanya Alasdair Gant2, Bryan Williams3, Tariq Enver4.   

Abstract

BACKGROUND: The reasons why some patients with COVID-19 develop pneumonia and others do not are unclear. To better understand this, we used multiparameter flow cytometry to profile circulating leukocytes from non-immunocompromised adult patients with PCR-proven COVID-19 and specifically compared those with mild symptoms with those who had developed pneumonia.
METHODS: Using clinically validated antibody panels we studied leukocytes from 29 patients with PCR-proven COVID-19. Ten were hypoxic requiring ventilatory support, eleven were febrile but otherwise well, and eight were convalescing having previously required ventilatory support. Additionally, we analysed patients who did not have COVID-19 but received ventilatory support for other reasons. We examined routine Full Blood Count (FBC) specimens that were surplus to routine diagnostic requirements; normal ranges were established in a historic group of healthy volunteers.
FINDINGS: We observed striking and unexpected differences in cells of the innate immune system. Levels of CD11b and CD18, which together comprise Complement Receptor 3 (CR3), were increased in granulocytes and monocytes from hypoxic COVID-19 patients, but not in those with COVID-19 who remained well, or in those without COVID-19 but ventilated for other reasons. Granulocyte and monocyte numbers were unchanged, however Natural Killer (NK) cell numbers were two-fold higher than normal in COVID-19 patients who remained well.
INTERPRETATION: CR3 is central to leukocyte activation and subsequent cytokine release in response to infection. It is also a fibrinogen receptor, and its over-expression in granulocytes and monocytes of patients with respiratory failure tables it as a candidate effector of both the thrombotic and inflammatory features of COVID-19 pneumonia, and both a biomarker of impending respiratory failure and potential therapeutic target. NK cells are innate immune cells that retain immunological memory. Rapid expansion of memory NK cells targeting common antigens shared with other Coronaviruses may explain why most patients with COVID-19 do not develop respiratory complications. Understanding the innate immune response to SARS-CoV-may uncover why most infected individuals experience mild symptoms, and inform a preventive approach to COVID-19 pneumonia in the future. Crown
Copyright © 2020. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COVID-19; Complement receptor 3; Flow cytometry; Hypoxia; Immunology and inflammation; Therapeutics

Mesh:

Substances:

Year:  2020        PMID: 32771640     DOI: 10.1016/j.ijid.2020.08.004

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  14 in total

1.  COVID-19 and myeloid cells: complex interplay correlates with lung severity.

Authors:  Franco R D'Alessio; Nicola M Heller
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

2.  Innate cell response in severe SARS-CoV-2 infection in children: Expression analysis of CD64, CD18 and CD11a.

Authors:  A García-Salido; M Á García-Teresa; I Leoz-Gordillo; A Martínez de Azagra-Garde; M Cabrero-Hernández; M Ramirez-Orellana
Journal:  Med Intensiva       Date:  2020-09-30       Impact factor: 2.491

Review 3.  A double edged-sword - The Complement System during SARS-CoV-2 infection.

Authors:  Lazara Elena Santiesteban-Lores; Thais Akemi Amamura; Tiago Francisco da Silva; Leonardo Moura Midon; Milena Carvalho Carneiro; Lourdes Isaac; Lorena Bavia
Journal:  Life Sci       Date:  2021-02-17       Impact factor: 5.037

4.  Viral arthralgia a new manifestation of COVID-19 infection? A cohort study of COVID-19-associated musculoskeletal symptoms.

Authors:  Caroline Wei Shan Hoong; Muhammad Nakib Monjur E Amin; Teck Choon Tan; Jer En Lee
Journal:  Int J Infect Dis       Date:  2021-01-18       Impact factor: 3.623

5.  Utilizing IoT to design a relief supply chain network for the SARS-COV-2 pandemic.

Authors:  Ali Zahedi; Amirhossein Salehi-Amiri; Neale R Smith; Mostafa Hajiaghaei-Keshteli
Journal:  Appl Soft Comput       Date:  2021-02-24       Impact factor: 6.725

6.  Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.

Authors:  Gergely Tibor Kozma; Tamás Mészáros; Tamás Bakos; Mark Hennies; Dániel Bencze; Barbara Uzonyi; Balázs Győrffy; Edward Cedrone; Marina A Dobrovolskaia; Mihály Józsi; János Szebeni
Journal:  Front Immunol       Date:  2021-04-28       Impact factor: 7.561

7.  Innate cell response in severe SARS-CoV-2 infection in children: Expression analysis of CD64, CD18 and CD11a.

Authors:  A García-Salido; M Á García-Teresa; I Leoz-Gordillo; A Martínez de Azagra-Garde; M Cabrero-Hernández; M Ramirez-Orellana
Journal:  Med Intensiva (Engl Ed)       Date:  2022-01

Review 8.  Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19.

Authors:  Danielle Brain; Alex Plant-Hately; Bethany Heaton; Usman Arshad; Christopher David; Christian Hedrich; Andrew Owen; Neill J Liptrott
Journal:  Adv Drug Deliv Rev       Date:  2021-06-25       Impact factor: 17.873

9.  Complement and protection from tissue injury in COVID-19.

Authors:  Alberto Ortiz
Journal:  Clin Kidney J       Date:  2020-10-04

10.  Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection.

Authors:  Ioannis V Kostopoulos; Nikolaos Orologas-Stavrou; Pantelis Rousakis; Chrysanthi Panteli; Ioannis Ntanasis-Stathopoulos; Ioanna Charitaki; Eleni Korompoki; Maria Gavriatopoulou; Efstathios Kastritis; Ioannis P Trougakos; Meletios-Athanasios Dimopoulos; Ourania E Tsitsilonis; Evangelos Terpos
Journal:  Microorganisms       Date:  2021-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.